Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PETER J GAGIANAS

Allopathic & Osteopathic Physicians Family Medicine

NPI
1417975384
CMS profile
154518
Location
MC MURRAY, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$9,087.37

38 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $8,472.80 5
Food and Beverage $614.57 33

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PETER J GAGIANAS

NPI 1417975384 · CMS profile ID 154518

Allopathic & Osteopathic Physicians / Family Medicine

MC MURRAY, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417975384?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PETER J GAGIANAS, NPI 1417975384, CMS profile ID 154518. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417975384?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PETER J GAGIANAS, NPI 1417975384, CMS profile ID 154518. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417975384?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PETER J GAGIANAS, NPI 1417975384, CMS profile ID 154518, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–38 of 38 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417975384?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

38 matching records · $9,087.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 38 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–38 of 38.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $12.1806/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700383581 CMS
Novartis Pharmaceuticals Corporation $21.1106/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659676979 CMS
GlaxoSmithKline, LLC. $15.4406/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670621253 CMS
GlaxoSmithKline, LLC. $16.3005/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671529129 CMS
Amgen Inc. $16.6205/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662871093 CMS
Astellas Pharma US Inc $16.3305/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655567029 CMS
Amarin Pharma Inc. $13.1605/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699154789 CMS
GlaxoSmithKline, LLC. $14.3705/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671453577 CMS
Novo Nordisk Inc $12.5505/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669561321 CMS
GlaxoSmithKline, LLC. $14.5505/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671396966 CMS
Lilly USA, LLC $13.5704/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658083479 CMS
GlaxoSmithKline, LLC. $13.1704/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670990173 CMS
GlaxoSmithKline, LLC. $17.0804/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670725049 CMS
Novo Nordisk AS $261.6004/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543491 CMS
Novo Nordisk AS $59.2904/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543493 CMS
Novo Nordisk AS $7,848.2204/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543495 CMS
Novo Nordisk AS $261.6004/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543497 CMS
Novo Nordisk AS $42.0904/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543499 CMS
Novo Nordisk AS $84.5604/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544753 CMS
Novo Nordisk AS $59.6804/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544755 CMS
GlaxoSmithKline, LLC. $15.0404/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670620213 CMS
Novo Nordisk Inc $12.0604/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669515955 CMS
PFIZER INC. $16.3203/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671918427 CMS
GlaxoSmithKline, LLC. $14.9003/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670213737 CMS
Merck Sharp & Dohme Corporation $14.0403/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695421629 CMS
GlaxoSmithKline, LLC. $14.6803/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670733461 CMS
Amgen Inc. $14.8702/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662871089 CMS
Novo Nordisk Inc $14.2302/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668749229 CMS
Astellas Pharma US Inc $17.4202/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655567025 CMS
Amgen Inc. $20.4202/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662871085 CMS
GlaxoSmithKline, LLC. $12.1202/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671131533 CMS
GlaxoSmithKline, LLC. $15.5002/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671533433 CMS
Astellas Pharma US Inc $17.8202/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655567021 CMS
Amgen Inc. $19.7101/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662871081 CMS
GlaxoSmithKline, LLC. $15.6801/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671109294 CMS
Lilly USA, LLC $10.7901/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658083481 CMS
Amgen Inc. $16.6201/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662871087 CMS
Lilly USA, LLC $11.6801/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658066325 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,087.37 38
PY2020 $27.80 2
PY2021 $501.56 23
PY2022 $376.51 23
PY2024 $67.91 2
PY2025 $20.35 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,125.10 1
PY2022 Principal investigator $27,034.10 4
PY2021 Principal investigator $55,143.92 142
PY2020 Principal investigator $43,019.42 143
PY2019 Principal investigator $58,558.98 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

142 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Esperion Therapeutics, Inc. $1,204.51 12/27/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838457575
Principal investigator 1 Esperion Therapeutics, Inc. $105.00 12/27/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838457583
Principal investigator 1 Novo Nordisk AS $2,092.50 12/22/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810732713
Principal investigator 1 Novo Nordisk AS $500.00 12/22/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
NN9535-4416 No dispute reported 06/30/2026 811347121
Principal investigator 1 Novo Nordisk AS $25.06 12/16/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810732703
Principal investigator 1 Novo Nordisk AS $3,000.00 12/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
NN9535-4416 No dispute reported 06/30/2026 810774353
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449843
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449851
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449857
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449865
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449873
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449881
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449887
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449895
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449903
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449911
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449917
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449925
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449933
Principal investigator 1 Novo Nordisk AS $25.06 11/18/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811380569
Principal investigator 1 Novo Nordisk AS $23.06 11/09/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810850373
Principal investigator 1 Novo Nordisk AS $23.06 11/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849525
Principal investigator 1 Novo Nordisk AS $585.00 10/27/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849489
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436157
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436163
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436171
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436179
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436187
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436195
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436203
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436209
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436217
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436223
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436231
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436239
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436247
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436255
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436263
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436269
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/21/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838436277
Principal investigator 1 Novo Nordisk AS $922.50 09/27/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849479
Principal investigator 1 Novo Nordisk AS $23.06 09/16/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849505
Principal investigator 1 Novo Nordisk AS $337.50 08/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811561615
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 08/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838429795
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 08/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838429803
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 08/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838429811
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 08/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838429819
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 08/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838429827
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 08/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838429835
Principal investigator 1 Novo Nordisk AS $23.06 08/18/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810732719
Principal investigator 1 Novo Nordisk AS $23.06 08/09/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810850383
Principal investigator 1 Novo Nordisk AS $23.06 08/02/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849495
Principal investigator 1 Novo Nordisk AS $675.00 07/28/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849515
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427907
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427915
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427922
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427931
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427939
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427947
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427955
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427961
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427969
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427977
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427985
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427995
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428003
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428009
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428017
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 07/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428025
Principal investigator 1 Esperion Therapeutics, Inc. $3,450.00 07/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427241
Principal investigator 1 Esperion Therapeutics, Inc. $420.00 07/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838427249
Principal investigator 1 Novo Nordisk AS $675.00 06/28/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849575
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 06/22/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420025
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 06/22/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420033
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 06/22/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420041
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 06/22/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420049
Principal investigator 1 Novo Nordisk AS $23.06 06/17/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811380579
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 06/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413597
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 06/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413602
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 06/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413609
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 06/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413617
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 06/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413625
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 06/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413633
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 06/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413641
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 06/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413649
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 06/01/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413657
Principal investigator 1 Novo Nordisk AS $23.06 05/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849545
Principal investigator 1 Novo Nordisk AS $23.06 05/11/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811561631
Principal investigator 1 Novo Nordisk AS $40.75 05/06/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810732729
Principal investigator 1 Novo Nordisk AS $37.20 05/06/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849535
Principal investigator 1 Novo Nordisk AS $60.00 05/06/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811380599
Principal investigator 1 Novo Nordisk AS $19.75 05/06/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811380609
Principal investigator 1 Novo Nordisk AS $23.25 05/06/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811561621
Principal investigator 1 Novo Nordisk AS $23.06 05/03/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810732693
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408203
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408211
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408219
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408227
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408235
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408243
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408249
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408257
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408265
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408273
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838408281
Principal investigator 1 Novo Nordisk AS $750.00 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
NN9535-4416 No dispute reported 06/30/2026 810774345
Principal investigator 1 Novo Nordisk AS $1,012.50 04/23/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849565
Principal investigator 1 Novo Nordisk AS $675.00 03/29/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811561651
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 03/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838400915
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 03/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838400923
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 03/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838400931
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 03/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838400939
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 03/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838400947
Principal investigator 1 Novo Nordisk AS $23.06 03/18/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811561605
Principal investigator 1 Novo Nordisk AS $250.00 02/24/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810849555
Principal investigator 1 Novo Nordisk AS $675.00 02/24/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811380619
Principal investigator 1 Novo Nordisk AS $130.00 02/24/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811561641
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 02/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394025
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 02/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394033
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 02/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394041
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 02/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394047
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 02/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394055
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 02/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394063
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 02/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394071
Principal investigator 1 Esperion Therapeutics, Inc. $32.00 02/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394076
Principal investigator 1 Esperion Therapeutics, Inc. $32.00 02/19/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838394083
Principal investigator 1 Novo Nordisk AS $23.06 02/17/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811561595
Principal investigator 1 Novo Nordisk AS $41.06 02/09/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811561585
Principal investigator 1 Novo Nordisk AS $41.06 02/03/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 810732683
Principal investigator 1 Novo Nordisk AS $337.50 01/26/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 811380559
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838388991
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838388999
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838389007
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838389015
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838389023
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838389187
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838389203
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838389210
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838389219
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838389226
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838389233
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 01/25/2021 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838389241